Biotech Stocks in Focus: Amgen Drops 10% Amid Clinical Trial Mislink

Five biotech stocks are in focus today, according to MarketBeat's stock screener tool. These companies include Amgen (AMGN), Moderna (MRNA), Halozyme Therapeutics (HALO), Gilead Sciences (GILD), and AbbVie (ABBV). Biotech stocks can offer substantial growth potential but often carry higher risks due to dependence on clinical-trial results, regulatory approvals, intellectual-property protection, and funding.

Amgen, a leading developer of human therapeutics, saw its stock drop 10% after it was mistakenly linked to a trial it did not even run. Moderna, another prominent biotech company, is working on messenger RNA therapeutics and vaccines for various diseases. Halozyme Therapeutics focuses on proprietary enzymes and devices, while Gilead Sciences discovers and develops medicines in areas of unmet medical need.

AbbVie, the fifth stock on MarketBeat's list, offers a range of pharmaceuticals, including Humira, Skyrizi, and Rinvoq. The company's stock volume has been high recently, indicating investor interest. While these biotech stocks have growth potential, investors should be aware of their associated risks.